Multi-Institutional, Prospective, Randomized, Double-Blind, Placebo-Controlled Phase Iib Trial Of The Tumor Lysate, Particle-Loaded, Dendritic Cell (Tlpldc) Vaccine To Prevent Recurrence In High-Risk Melanoma Patients: A Subgroup Analysis

Robert Connor Chick,Mark B. Faries,Diane F. Hale,Phillip M. Kemp Bohan,Annelies Hickerson,Timothy J. Vreeland,John William Myers,Jessica L. Cindass,Tommy A. Brown,John Robert Hyngstrom,James W. Jakub,Jeffrey J. Sussman,Adam C. Berger,Montaser F. Shaheen,G. Travis Clifton,Thomas Wagner,George Earl Peoples

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 7|浏览53

暂无评分

摘要

The TLPLDC vaccine improved DFS in patients completing the primary vaccine series, particularly in the resected stage IV patients. The efficacy of the TLPLDC vaccine will be confirmed in a phase III study evaluating adjuvant TLPLDC + CPI versus Placebo + CPI in resected stage IV melanoma patients.

查看译文

关键词

cancer vaccine,immunotherapy,melanoma,personalized medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要